Table 2.
Treatment | Baseline | 8-Weeks | 16-Weeks | |||||
---|---|---|---|---|---|---|---|---|
N | M (SE) | N | M (SE) | N | M (SE) | |||
Perceived Stress Scale | ||||||||
Total | Placebo | 69 | 14.20 (0.72) | 62 | 13.02 (0.78) | 58 | 16.26 (0.64) | |
MV | 64 | 15.30 (0.70) | 60 | 14.80 (0.79) | 56 | 17.52 (0.78) | ||
Males | Placebo | 30 | 13.60 (1.16) | 27 | 11.63 (0.91) | 27 | 15.63 (0.98) | |
MV | 28 | 15.32 (1.09) | 26 | 13.65 (1.03) | 24 | 17.04 (1.34) | ||
Females | Placebo | 39 | 14.67 (0.93) | 35 | 14.09 (1.17) | 31 | 16.81 (0.85) | |
MV | 36 | 15.28 (0.94) | 34 | 15.68 (1.14) | 32 | 17.88 (0.94) | ||
Blood Measures | ||||||||
B6 | Placebo | 50 | 114.08 (10.27) | 121.32 (19.32) | 130.84 (24.14) | |||
MV | 43 | 111.70 (9.36) | 631.40 (38.17) | 567.67 (31.80) | ||||
B12 | Placebo | 50 | 314.60 (14.48) | 323.9000 (14.84) | 318.9400 (15.46) | |||
MV | 44 | 289.25 (12.11) | 371.0909 (18.44) | 391.9773 (15.32) | ||||
RCF | Placebo | 49 | 944.96 (21.94) | 952.55 (26.09) | 1039.65 (32.38) | |||
MV | 41 | 933.27 (34.99) | 1051.44 (46.11) | 1237.05 (48.43) | ||||
HCy | Placebo | 51 | 10.6137 (0.22) | 10.8725 (0.29) | 10.4098 (0.33) | |||
MV | 45 | 10.8444 (0.35) | 9.8578 (0.27) | 9.2244 (0.27) |